



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 105766

TO: David Lukton
Location: CM-1/9B05/9B01
Art Unit: 1653
Friday, October 10, 2003

Case Serial Number: 09/913538

From: Noble Jarrell
Location: Biotech/Chem Library
CM1-6B03 87
Phone: 305-7843
Noble.jarrell@uspto.gov

Search Notes

SEARCH REQUEST FORM

Scientific and Technical Information Center


Requester's Full Name: David Lukton Examiner #: 71263 Date: 10-09-03
 Art Unit: 1653 Phone Number 30 8.3213 Serial Number: 09-913538
 Mail Box and Bldg/Room Location: Mail Box: 9B01; Exn Am 9B05 Results Format Preferred (circle): PAPER DISK E-MAIL

Title of Invention: Heterocyclic Compounds, Intermediates Thereof and Elastase Inhibitors

Applicants: SATO, FUMINORI; INOUE, YASUNAO;
 OMODANI, TOMOKI; SHIRATAKE, RYOTARO; HONDA, SEIJI; KOMIYA,
 MASANOBU; TAKEMURA, TADASHI

Earliest Priority Date: 3/3/99

STUD
OCT-9 2003
RECEIVED




X = -CH₂- or -CO-

R¹ = alkyl

R² = alkyl

R³ = -CF₃ or -CCl₃ or hydrogen or -CH₂Br or



STAFF USE ONLY

Type of Search

Vendors and co.

Searcher: Noble Jurrell/P. S. Suman STN _____
 Searcher Phone #: 308 305 8743 AA Sequence (#) _____ Dialog _____
 Searcher Location: _____ Structure (#) _____ Questel/Orbit _____
 Date Searcher Picked Up: _____ Bibliographic _____ Dr. Link _____
 Date Completed: Oct 10, 2003 Litigation _____ Lexis/Nexis _____
 Searcher Prep & Review Time: _____ Fulltext _____ Sequence Systems _____
 Clerical Prep Time: _____ Patent Family _____ WWW/Internet _____
 Online Time: _____ Other _____ Other (specify) _____

=> b hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

4.51

312.13

FILE 'HCAPLUS' ENTERED AT 14:21:30 ON 10 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Oct 2003 VOL 139 ISS 16



FILE LAST UPDATED: 9 Oct 2003 (20031009/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> d stat que

L3

STR



Page 1-A



Page 1-B

VAR G1=CH2/33

VAR G2=44/35/H
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
 L6 16 SEA FILE=REGISTRY SSS FUL L3
 L10 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L6

=> d ibib abs hitrn 1-4

L10 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2003:644386 HCAPLUS
 DOCUMENT NUMBER: 139:191421
 TITLE: Pharmaceuticals, chymase inhibitors, and inhibitors
 for increased vascular permeability, containing
 pyrrolidine-containing peptides
 INVENTOR(S): Deguchi, Takashi; Shiratake, Ryotaro; Sato, Fuminori;
 Fujitani, Takekazu; Honda, Yayoi; Kiyoshi, Akihiko;
 Notake, Mitsue; Showell, Graham Andrew; Boyle, Robert
 George; Klair, Sukhbinder Singh
 PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 44 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003231645	A2	20030819	JP 2002-29496	20020206
PRIORITY APPLN. INFO.:			JP 2002-29496	20020206
OTHER SOURCE(S):	MARPAT 139:191421			
GI				



AB The pharmaceuticals, for treatment of allergy, inflammation, etc., contain pyrrolidine-contg. peptides I [R1 = cycloalkyl, naphthyl, thienyl, etc.; R2 = H, alkyl, etc.; R3 = (un)substituted unsatd. monocyclic heterocyclyl, (un)substituted (un)satd. monocyclic heterocycle fused to benzene ring or pyridine ring, N-heterocyclyl-lower alkyl; n = 0-3] or their physiol. acceptable salts. N-[(1S)-2-[(2S)-2-[N-[(1S)-1-(benzo[b]thiophen-3-ylmethyl)-3,3,3-trifluoro-2-oxopropyl]carbamoyl]pyrrolidinyl]-1-

(methylethyl)-2-oxoethyl](3,5-dimethylisoxazol-4-yl)carboxamide (II) (prepn. given) inhibited monkey chymase and human chymase with IC₅₀ of 3.8 and 55 nM, resp. II (at 100 mg/kg p.o.) showed 34% inhibition of chymase-induced leakage of Evans Blue dye from the vein of guinea pigs. The concn. of II in plasma of mice 1 h after oral administration of a suspension contg. II at 1 mg/mL was 0.48 .mu.g/mL. II (at 300 mg/kg p.o. once a day for 2 wk) showed no toxicity in mice. Oral and topical formulation examples are given.

IT 402733-08-8P 402733-09-9P 402733-10-2P
402733-11-3P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrrolidine-contg. tripeptides for pharmaceuticals which inhibit chymase and increased vascular permeability)

L10 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:359856 HCAPLUS

DOCUMENT NUMBER: 136:369997

TITLE: Pharmaceuticals containing heterocyclyl group-containing prolines as water-soluble inhibitors of human neutrophil elastase

INVENTOR(S): Sato, Fuminori; Inoue, Yasuharu; Omotani, Tomoki; Shiratake, Ryotaro; Honda, Seiji; Komiya, Masanobu; Takemura, Tadashi

PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 41 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002138048	A2	20020514	JP 2001-251265	20010822
PRIORITY APPLN. INFO.:			JP 2000-254746	A 20000825
OTHER SOURCE(S):		MARPAT 136:369997		

GI



AB Title compds. I [A, B = (oxo-substituted) lower alkylene D = Q; D1 = (oxo-substituted) CH₂, (oxo-substituted) CH₂CH₂; the ring G = 5- to

14-membered monocyclic (un)satd. (un)substituted heterocycle residue (having addnl. N, O, and/or S); R1, R2 = lower alkyl; R3 = (CX1X2)n(CH2)mY1; X1, X2 = halo; Y1 = H, halo, lower alkoxycarbonyl, lower alkylaminocarbonyl, etc.] or their physiol. acceptable salts are prepd. and are esp. useful for therapeutic and prophylactic treatment of acute lung disease, e.g. emphysema and acute respiratory distress syndrome. Thus, condensation of 2-[(3-tert-butoxycarbonylmethyl-2-oxo-1-imidazolidinyl)]acetic acid with L-valyl-N-[(1S,2S)-(3,3,3-trifluoro-1-isopropyl-2-hydroxypropyl)]-L-prolinamide HCl salt gave the corresponding amide, which was oxidized with Dess-Martin reagent and deprotected to afford 2-(3-carboxymethyl-2-oxo-1-imidazolidinyl)acetyl-L-valyl-N-[(1S)-3,3,3-trifluoro-1-isopropyl-2-oxopropyl]-L-prolinamide. The product inhibited human neutrophil elastase at IC50 value of 0.010 .mu.M and showed much better water soly. than ONO-5046.

IT **291778-77-3P**

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyl group-contg. prolines as water-sol. inhibitors of human neutrophil elastase)

IT **291778-87-5P 291778-99-9P 291779-01-6P****291779-07-2P 291779-09-4P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyl group-contg. prolines as water-sol. inhibitors of human neutrophil elastase)

IT **291778-76-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heterocyclyl group-contg. prolines as water-sol. inhibitors of human neutrophil elastase)

IT **291778-88-6P 291779-00-5P 291779-02-7P****291779-08-3P 291779-10-7P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of heterocyclyl group-contg. prolines as water-sol. inhibitors of human neutrophil elastase)

L10 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:171894 HCAPLUS

DOCUMENT NUMBER: 136:217051

TITLE: Preparation of proline derivatives for use as chymase inhibitor

INVENTOR(S): Deguchi, Takashi; Shiratake, Ryotaro; Sato, Fuminori; Fujitani, Buichi; Honda, Yayoi; Kiyoshi, Akihiko; Notake, Mitsue; Showell, Graham Andrew; Boyle, Robert George; Klair, Sukhbinder Singh

PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018378	A1	20020307	WO 2001-JP7137	20010821
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2001078782 A5 20020313 AU 2001-78782 20010821
 EP 1313730 A1 20030528 EP 2001-956986 20010821
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 PRIORITY APPLN. INFO.: GB 2000-21315 A 20000830
 WO 2001-JP7137 W 20010821
 OTHER SOURCE(S): MARPAT 136:217051
 GI



AB Novel pyrrolidine derivs. I [R1 = cycloalkyl, Ph, naphthyl, tetrahydronaphthyl, indanyl, thienyl, furyl, indolyl, dihydroindolyl, benzofuryl, dihydrobenzofuryl, benzothienyl or an S-mono- or dioxide, or dihydrobenzothienyl, where the Ph, naphthyl and benzothienyl groups may have 1-3 substituents and the indolyl and dihydroindolyl groups may be N-substituted; R2 = H, alkyl, phenylalkyl, cycloalkyl, or cycloalkylalkyl; R3 is an (un)substituted monocyclic heterocyclic group, benzene- or pyridine-fused heterocyclic group, etc.; R4, R5 = H or OH, but both are not simultaneously H or both form oxo; n is 0-3] or their salts were prep'd. as chymase inhibitors. Thus, N-[(1S)-2-[(2S)-2-[N-[(1S)-1-(benzo[b]thiophen-3-ylmethyl)-3,3,3-trifluoro-2-oxopropyl]carbamoyl]pyrrolidinyl]-1-(methylethyl)-2-oxoethyl](3,5-dimethylisoxazol-4-yl)carboxamide was prep'd. via coupling reactions of (2S,3S)-3-amino-4-[benzo[b]thiophen-3-yl]-1,1,1-trifluoro-2-butanol hydrochloride, N-(tert-butoxycarbonyl)-L-valyl-L-proline, and 3,5-dimethyl-4-isoxazolecarboxylic acid and showed IC50 = 3.8 and 55 nM for inhibition of monkey or human chymase (in vitro assay).


IT 402733-08-8P 402733-09-9P 402733-10-2P
 402733-11-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of proline derivs. for use as chymase inhibitors)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2000:628158 HCAPLUS
 DOCUMENT NUMBER: 133:223051
 TITLE: Preparation of proline-containing peptides,

intermediates thereof, and elastase inhibitors
 INVENTOR(S): Sato, Fuminori; Inoue, Yasunao; Omodani, Tomoki;
 Shiratake, Ryotaro; Honda, Seiji; Komiya, Masanobu;
 Takemura, Tadashi
 PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052032	A1	20000908	WO 2000-JP1022	20000223
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2000256396	A2	20000919	JP 1999-56052	19990303
EP 1157998	A1	20011128	EP 2000-905282	20000223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008600	A	20011226	BR 2000-8600	20000223
AU 758739	B2	20030327	AU 2000-26902	20000223
AU 2000026902	A5	20000921		
NZ 513594	A	20030429	NZ 2000-513594	20000223
ZA 2001006514	A	20020510	ZA 2001-6514	20010808
PRIORITY APPLN. INFO.:			JP 1999-56052	A 19990303
			WO 2000-JP1022	W 20000223
OTHER SOURCE(S):		MARPAT 133:223051		
GI				



AB Heterocyclic compds. represented by general formula [I; A, B = optionally oxo-substituted lower alkyl; D = mono- or bicyclic heterocyclic group Q; wherein D1 = optionally oxo-substituted CH₂ or CH₂CH₂; ring G = (un)substituted 5-14 membered mono- or bicyclic (un)satd. heterocyclic ring; R1, R2 = lower alkyl; R3, R4 = H or OH, or R1 and R2 together represents oxo; R5 = (CX₁X₂)_n(CH₂)_mY₁; wherein X₁, X₂ = halo; Y₁ = H,

halo, lower alkoxy carbonyl, lower alkylaminocarbonyl, aralkylaminocarbonyl, aralkyloxycarbonyl, etc.], its esters or salts thereof are prepd. Also claimed is human neutrophilic elastase inhibitors contg. I as the active ingredient. Thus, oxidn. of 2-(3-tert-butoxycarbonylmethyl-2-oxo-1-imidazolidinyl)acetyl-L-valyl-N-[(1S,2S)-3,3,3-trifluoro-1-isopropyl-2-hydroxypropyl]-L-prolinamide with Dess-Martin reagent in CH₂Cl₂ at room temp. for 1 h, followed by treatment with CF₃CO₂H gave the title compd. (II; R = Q1, R5 = CF₃) (III). III and II (R = Q2, R5 = benzoxazol-2-yl) showed IC₅₀ of 0.010 and 0.005 .mu.g/mL against human neutrophilic elastase, resp. Pharmaceutical formulations contg. I were also prepd.

IT 291778-77-3P 291778-87-5P 291778-99-9P

291779-01-6P 291779-07-2P 291779-09-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of proline-contg. peptides, intermediates thereof, and elastase inhibitors)

IT 291778-76-2P 291778-88-6P 291779-00-5P

291779-02-7P 291779-08-3P 291779-10-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of proline-contg. peptides, intermediates thereof, and elastase inhibitors)

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> b caold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
22.15	334.28

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.60	-2.60

CA SUBSCRIBER PRICE

FILE 'CAOLD' ENTERED AT 14:24:24 ON 10 OCT 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 16

L11 0 L6

=> b reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	334.68

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.60

FILE 'REGISTRY' ENTERED AT 14:24:48 ON 10 OCT 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 OCT 2003 HIGHEST RN 601453-92-3
 DICTIONARY FILE UPDATES: 8 OCT 2003 HIGHEST RN 601453-92-3

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can l6 tot

L6 ANSWER 1 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 402733-11-3 REGISTRY
 CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2-oxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(benzo[b]thien-2-ylmethyl)-3,3,3-trifluoro-2-oxopropyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H42 F3 N5 O7 S
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:191421

REFERENCE 2: 136:217051

L6 ANSWER 2 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
RN 402733-10-2 REGISTRY
CN L-Prolinamide, N-[[3-(carboxymethyl)-2-oxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(benzo[b]thien-2-ylmethyl)-3,3,3-trifluoro-2-oxopropyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C29 H34 F3 N5 O7 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:191421

REFERENCE 2: 136:217051

L6 ANSWER 3 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
RN 402733-09-9 REGISTRY
CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2-oxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(2-naphthalenylmethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H44 F3 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:191421

REFERENCE 2: 136:217051

L6 ANSWER 4 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
RN 402733-08-8 REGISTRY
CN L-Prolinamide, N-[[3-(carboxymethyl)-2-oxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(2-naphthalenylmethyl)-2-oxopropyl]- (9CI)
(CA INDEX NAME)
FS STEREOSEARCH
MF C31 H36 F3 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:191421

REFERENCE 2: 136:217051

L6 ANSWER 5 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 291779-10-7 REGISTRY
 CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2-oxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(2-benzoxazolylcarbonyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H46 N6 O8
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 6 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 291779-09-4 REGISTRY
 CN L-Prolinamide, N-[[3-(carboxymethyl)-2-oxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(2-benzoxazolylcarbonyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H38 N6 O8
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 7 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
RN 291779-08-3 REGISTRY
CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(2-benzoxazolylcarbonyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H48 N6 O9
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 8 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 291779-07-2 REGISTRY
 CN L-Prolinamide, N-[[3-(carboxymethyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(2-benzoxazolylcarbonyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C31 H40 N6 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 9 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 291779-02-7 REGISTRY
 CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(2-benzoxazolylcarbonyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H44 N6 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 10 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN

RN 291779-01-6 REGISTRY

CN L-Prolinamide, N-[[3-(carboxymethyl)-2,5-dioxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(2-benzoxazolylcarbonyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C29 H36 N6 O9

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 11 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 291779-00-5 REGISTRY
 CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2,4-dioxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(2-benzoxazolylcarbonyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C33 H44 N6 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 12 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 291778-99-9 REGISTRY
 CN L-Prolinamide, N-[[3-(carboxymethyl)-2,4-dioxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-1-(2-benzoxazolylcarbonyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C29 H36 N6 O9
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)


REFERENCE 1: 136:369997

REFERENCE 2: 133:223051


L6 ANSWER 13 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
RN 291778-88-6 REGISTRY
CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2,5-dioxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H40 F3 N5 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 14 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN

RN 291778-87-5 REGISTRY

CN L-Prolinamide, N-[[3-(carboxymethyl)-2,5-dioxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C23 H32 F3 N5 O8

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 15 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 291778-77-3 REGISTRY
 CN L-Prolinamide, N-[[3-(carboxymethyl)-2-oxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H34 F3 N5 O7
 SR CA
 LC STN Files: CA, CAPLUS, DRUGNL, DRUGUPDATES, SYNTHLINE, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


2 REFERENCES IN FILE CA (1907 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051

L6 ANSWER 16 OF 16 REGISTRY COPYRIGHT 2003 ACS on STN
 RN 291778-76-2 REGISTRY
 CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2-oxo-1-imidazolidinyl]acetyl]-L-valyl-N-[(1S)-3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C27 H42 F3 N5 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:369997

REFERENCE 2: 133:223051



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor
308-4258, CM1-1E01

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 - Circ. Desk

